The Apex Times
Above the Noise
Business Wire
BusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex TimesBusinessFTC sends about $9.8 million to roughly 65,000 Walmart wire-transfer victims, company faces renewed scrutiny on payment fraud controlsThe Apex TimesBusinessEvercore ISI Says Apple’s iPhone Duo Pre-Order Demand Is “Solidly Out of the Gate,” With Delivery Dates Pushed to Late JanuaryThe Apex TimesBusinessExxonMobil says stronger refining margins could add $4.5 billion to third-quarter Energy Products profitThe Apex TimesBusinessFAA approval for Boeing 737 MAX 10 appears imminent, but Wall Street still trims outlooksThe Apex TimesBusinessTesla’s earnings track record suggests big stock moves, often to the downsideThe Apex TimesBusinessGoogle’s Gemini heads to Geely’s overseas cars, turning AI assistance into an in-car platformThe Apex TimesBusiness“Walmart recession announcement” used to flag 2008 downturn is reportedly climbing again, economist saysThe Apex TimesBusinessBlackRock’s fixed-income investing is circling around AI-linked credit and emerging-market yields, Yahoo Finance saysThe Apex TimesBusinessMastercard launches a “global money platform” that pairs traditional currencies with stablecoins, building on its BVNK dealThe Apex TimesBusinessSEC approval opens standardized binary options tied to crypto-company metrics, not direct bets on Bitcoin priceThe Apex TimesBusinessCoca-Cola selected as KFC U.S. exclusive fountain beverage supplier starting in 2027The Apex TimesBusinessBarclays flags potential Tesla-SpaceX merger idea as analysts weigh AI, robotics and manufacturing synergiesThe Apex Times
Back to front
Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 26, 7:46 AM EDT

Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia

A favorable opinion from the EMA’s CHMP puts Lilly’s Jaypirca one step closer to potential approval in the European Union for adults with chronic lymphocytic leukemia, covering all lines of therapy.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly is advancing its cancer drug Jaypirca (pirtobrutinib) toward a broader regulatory footprint in Europe after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion, according to a report published by Yahoo Finance on June 26, 2026.

The CHMP recommendation relates to use in adults with chronic lymphocytic leukemia, or CLL, a type of blood cancer. The proposed scope covers treatment across all lines of therapy, meaning the therapy is intended to be usable regardless of where a patient is in their treatment path, from earlier lines to later ones.

A positive CHMP opinion does not itself grant marketing authorization across the European Union. Instead, it is a formal step in the EMA process that is followed by a decision from the European Commission, which typically considers CHMP recommendations before issuing a final approval for EU-wide use.

Lilly did not provide additional details in the Yahoo Finance post beyond the CHMP’s positive opinion and the stated intended patient population and line-of-therapy coverage. The report also does not spell out trial datasets, endpoints, comparative results versus existing therapies, or any conditions that could be attached to approval.

For Lilly, the development matters because CLL remains a large and active oncology market in Europe, where therapy selection is increasingly influenced by how well drugs perform across different treatment settings. A label that spans all lines of therapy can simplify prescribing decisions and may position a treatment more broadly when clinicians are deciding between multiple available options.

More broadly, the CHMP opinion underscores the EMA’s ongoing approach to reviewing oncology medicines using standardized, evidence-based assessments through its medicinal product committees. For patients and physicians, CHMP recommendations can be a meaningful announcement that an application met the agency’s scientific and regulatory thresholds, even though the ultimate EU approval still depends on the European Commission’s follow-through.

Still, the regulatory picture is not complete. The Yahoo Finance report did not indicate whether the CHMP opinion includes any restrictions, confirmatory study requirements, or timing expectations for the European Commission decision. Without those details, it is not possible to determine how quickly Jaypirca could become available for the described CLL population across the EU or whether the final authorization could differ from the CHMP recommendation.

Why It Matters

  • If finalized by the European Commission, the CHMP recommendation could expand Jaypirca’s commercial opportunity in one of Europe’s major oncology disease areas.
  • A label that covers all lines of therapy can increase flexibility for clinicians, potentially improving the drug’s relevance across patient journeys.
  • The update provides an important regulatory milestone, though final authorization and any conditions still remain to be determined.
  • Investors and analysts will likely watch for the European Commission’s timing and whether the final label matches the CHMP scope.

Sources

Key Facts

  • Eli Lilly’s Jaypirca (pirtobrutinib) received a positive opinion from the EMA’s CHMP, according to a June 26, 2026 Yahoo Finance report.
  • The CHMP recommendation is for adults with chronic lymphocytic leukemia (CLL).
  • The recommended indication covers use across all lines of therapy.
  • A CHMP positive opinion is part of the EMA process and is followed by a European Commission decision for final EU authorization.
  • The report did not include trial results, endpoints, or any label restrictions or conditions in the disclosed text.

Healthcare Related

Eli Lilly’s Jaypirca (pirtobrutinib) gets a positive EU CHMP recommendation for chronic lymphocytic leukemia | The Apex Times